BIORQ.US Biora Therapeutics, Inc.
- Market cap
- USD 452.00
- P/E
- -
- P/B
- -
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2024.
Is BIORQ.US undervalued?
Graham numberThe Graham number of Biora Therapeutics, Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Biora Therapeutics, Inc. fundamental analysis
No fundamental analysis for Biora Therapeutics, Inc. yet.
Biora Therapeutics, Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Biora Therapeutics, Inc.
Biora Therapeutics, Inc., a clinical-stage biotechnology company, engages in developing oral biotherapeutics in the United States. The company offers NaviCap, a targeted oral delivery platform for delivery of therapeutics in the gastrointestinal tract to enhance the treatment of inflammatory bowel diseases; and BioJet, a systemic oral delivery platform designs to replace injection with needle-free, oral delivery of large molecules for management of chronic diseases. The comp…
Full company profileBiora Therapeutics, Inc. financial statements
2024 annualized: Fiscal year 2024 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2024, the balance sheet is the latest quarter. Figures change when the annual report is published.
Biora Therapeutics, Inc. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 Anlz |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | 128M | 144M | 74.3M | 1.25M | 305K | 4.00K | 1.19M |
| Gross Profit | 35.9M | 43.5M | -19.1M | 1.25M | 305K | 4.00K | 1.04M |
| Operating Income | -114M | -140M | -108M | -118M | -61.8M | -67.1M | -63.4M |
| EBITDA | -109M | -135M | -106M | -165M | -37.4M | -114M | -18.9M |
| Net Income | -129M | -148M | -193M | -179M | -38.2M | -124M | -21.5M |
| EPS | -1,197 | -802 | -863 | -464 | -50 | -79 | -5.89 |
| Balance Sheet | |||||||
| Total Assets | 116M | 102M | 154M | 109M | 53.5M | 31.2M | 14.5M |
| Total Liabilities | 153M | 186M | 261M | 194M | 156M | 133M | 121M |
| Shareholders' Equity | -37.0M | -83.9M | -107M | -85.0M | -102M | -101M | -107M |
| Cash & Short-term Investments | 69.2M | 33.0M | 92.1M | 88.4M | 30.5M | 15.2M | 3.20M |
| Total Debt | 72.7M | 73.4M | 161M | 126M | 129M | 47.4M | 39.6M |
| Cash Flow | |||||||
| Operating Cash Flow | -65.1M | -106M | -166M | -167M | -64.4M | -48.5M | -42.9M |
| Capital Expenditure | 4.83M | 3.73M | 4.94M | 855K | 792K | 103K | 285K |
| Free Cash Flow | -70.0M | -110M | -171M | -168M | -65.2M | -48.6M | 11.1M |
| Ratios | |||||||
| ROA | -110.9% | -145.5% | -124.7% | -164.0% | -71.3% | -397.6% | -148.2% |
| Net Profit Margin | -100.9% | -102.8% | -259.1% | -14,316.0% | -12,510.5% | -3,102,875.0% | -1,807.8% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Biora Therapeutics, Inc. dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | USD 4.50M | 24 | - |
| 2018 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:10 on Oct 18, 2024.
Who owns Biora Therapeutics, Inc.
- Insiders 6.57%
- Institutions 77.24%
- Public & others 16.20%
- Shares outstanding 4.52M
- Free float 3.10M
Biora Therapeutics, Inc. company profile
- Company name
- Biora Therapeutics, Inc.
- Ticker
- BIORQ.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 58
- Fiscal year end
- December
- Address
- 4330 La Jolla Village Drive, San Diego, CA, United States, 92122
- Phone
- 833 727 2841
- Website
- bioratherapeutics.com
About Biora Therapeutics, Inc.
Biora Therapeutics, Inc., a clinical-stage biotechnology company, engages in developing oral biotherapeutics in the United States. The company offers NaviCap, a targeted oral delivery platform for delivery of therapeutics in the gastrointestinal tract to enhance the treatment of inflammatory bowel diseases; and BioJet, a systemic oral delivery platform designs to replace injection with needle-free, oral delivery of large molecules for management of chronic diseases. The company was formerly known as Progenity, Inc. and changed its name to Biora Therapeutics, Inc. in April 2022 to reflect its focus on its therapeutics pipeline. Biora Therapeutics, Inc. was founded in 2010 and is headquartered in San Diego, California. On May 27, 2025, the voluntary petition of Biora Therapeutics, Inc. for reorganization under Chapter 11 was converted to Chapter 7. It had filed for Chapter 11 bankruptcy on December 27, 2024.
Biora Therapeutics, Inc. management
5- Mr. Aditya P. Mohanty M.B.A.CEO & Director · born 1967
- Mr. Clarke Neumann J.D.Senior VP, General Counsel & Secretary · born 1964
- Mr. Kevin Howe Ph.D.Senior VP of Strategic Operations
- Dr. Paul Shabram M.B.A.Head of Technical Operations
- Mr. James Knight M.B.A.Head of Business Development